Logotype for ExpreS2ion Biotech Holding

ExpreS2ion Biotech (EXPRS2) investor relations material

ExpreS2ion Biotech Investing in Life Science 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ExpreS2ion Biotech Holding
Investing in Life Science 2025 summary25 Sep, 2025

Disease overview and market need

  • Breast cancer incidence is rising, with 2.3 million new cases and 700,000 deaths annually, projected to reach 3 million cases and 1 million deaths by 2040.

  • HER2-expressing tumors are present in 80% of cases, with up to 50% of these patients relapsing due to drug resistance.

  • Incidence in women under 50 has increased by nearly 80% since 1990, making it the leading cancer in this group.

  • The HER2 breast cancer market is valued at €11 billion annually, with the broader breast cancer market at €27 billion and growing 7% per year.

  • Addressable market for the new therapy is estimated at over €5 billion per year.

Therapeutic innovation and clinical progress

  • Developed an immunotherapy using a virus-like particle to induce a strong, targeted immune response against all four extracellular domains of the HER2 receptor.

  • This polyclonal antibody approach differs from current therapies, which target only one domain.

  • Preclinical data show robust antibody induction and tumor suppression in resistant breast cancer cell lines and mouse models.

  • Early phase 1 human data indicate significant HER2-specific antibody increases in the first patient.

  • Full treatment curve data for the first patient expected in December, with phase 1a safety readout in 2026 and phase 1b efficacy data from 27 patients by end of next year.

Development strategy and partnerships

  • Initial clinical focus is on metastatic patients who have failed standard therapies, with plans to move earlier in the treatment line.

  • Phase 2 proof-of-concept study will determine licensing and potential expansion into gastric cancer.

  • Licensing targeted after phase 2, with potential for early approval if data are strong; phase 3 would be conducted by a partner.

  • Signed a letter of intent with WuXi Vaccines for manufacturing and commercialization in China; collaboration is ongoing.

  • Agreement with Technical University of Denmark provides supercomputer access to accelerate early-stage drug development using AI.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next ExpreS2ion Biotech earnings date

Logotype for ExpreS2ion Biotech Holding
Q3 202513 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next ExpreS2ion Biotech earnings date

Logotype for ExpreS2ion Biotech Holding
Q3 202513 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops, produces, and delivers therapeutics or diagnostic proteins in Denmark and internationally. The company uses its expression system technology to offer services that include cell line development, screening of cell bank clones developed in the clients' host cell line of interest, analytical services comprising host cell line development, clone screening and base media optimization, process scale-up and GMP manufacturing. It also manufactures and distributes therapeutic proteins based on prokaryotic and eukaryotic expression systems using the GalXC protein expression system to EU/US chemical and health companies.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage